Gao Fei, Gao Jinqi, Wang Kuiyang, Song Lei
Intervention Treatment Department, The Second Hospital of Dalian Medical University, Dalian, China.
Front Surg. 2022 Aug 25;9:938305. doi: 10.3389/fsurg.2022.938305. eCollection 2022.
Transarterial chemoembolization with CalliSpheres® Microspheres (CSM-TACE) presents favorable efficacy and tolerable safety in several cancers, while its application in head and neck cancer (HNC) is unclear. Thus, the current pilot study aims to evaluate the efficacy and safety of CSM-TACE in treating HNC.
A total of 15 HNC patients receiving CSM-TACE at the Second Affiliated Hospital of Dalian Medical University from March 2017 to December 2021 were enrolled in this study. Moreover, treatment information, treatment response, progression-free survival (PFS), overall survival (OS), changes in liver and renal function indices, and adverse events were recorded.
There were nine patients receiving CSM-TACE as first-line treatment and six patients receiving CSM-TACE as second- or above-line treatment; meanwhile, there were seven, seven, and one patient undergoing one time, two times, and three times of CSM-TACE, respectively. Furthermore, the objective response rate (ORR) and the disease control rate (DCR) were 60.0% and 100%, respectively, at the first month; meanwhile, the ORR and the DCR were 53.3% and 73.3%, respectively, at the second month. Moreover, the 1-year PFS rate was 34.1%, and the 1-year OS rate was 38.9%. Additionally, no change in liver function indices (namely, total protein, albumin, total bilirubin, alanine aminotransferase, and aspartate aminotransferase) or in renal function indices (namely, creatinine and blood urea nitrogen) was found before and 1 month after treatment (all > 0.05). Meanwhile, no severe adverse events were found during and after CSM-TACE.
CSM-TACE illustrates favorable treatment response and survival benefits as well as a tolerable safety profile in HNC patients.
使用载药微球（CSM-TACE）进行经动脉化疗栓塞在多种癌症中显示出良好的疗效和可耐受的安全性，但其在头颈癌（HNC）中的应用尚不清楚。因此，本项初步研究旨在评估CSM-TACE治疗HNC的疗效和安全性。
本研究纳入了2017年3月至2021年12月在大连医科大学附属第二医院接受CSM-TACE治疗的15例HNC患者。此外，记录了治疗信息、治疗反应、无进展生存期（PFS）、总生存期（OS）、肝肾功能指标变化及不良事件。
9例患者接受CSM-TACE作为一线治疗，6例患者接受CSM-TACE作为二线或以上治疗；同时，分别有7例、7例和1例患者接受了1次、2次和3次CSM-TACE治疗。此外，第一个月时客观缓解率（ORR）和疾病控制率（DCR）分别为60.0%和100%；同时，第二个月时ORR和DCR分别为53.3%和73.3%。此外，1年PFS率为34.1%，1年OS率为38.9%。另外，治疗前和治疗后1个月肝功能指标（即总蛋白、白蛋白、总胆红素、谷丙转氨酶和谷草转氨酶）及肾功能指标（即肌酐和血尿素氮）均未发现变化（均>0.05）。同时，CSM-TACE治疗期间及治疗后未发现严重不良事件。
CSM-TACE在HNC患者中显示出良好的治疗反应、生存获益以及可耐受的安全性。
